Markus Hoffmann
#166,427
Most Influential Person Now
Researcher
Markus Hoffmann's AcademicInfluence.com Rankings
Markus Hoffmanncomputer-science Degrees
Computer Science
#10024
World Rank
#10517
Historical Rank
Computational Linguistics
#2507
World Rank
#2532
Historical Rank
Machine Learning
#4543
World Rank
#4594
Historical Rank
Artificial Intelligence
#4904
World Rank
#4968
Historical Rank
Download Badge
Computer Science
Markus Hoffmann's Degrees
- PhD Computer Science Stanford University
- Masters Computer Science University of California, Berkeley
- Bachelors Computer Science University of California, Berkeley
Similar Degrees You Can Earn
Why Is Markus Hoffmann Influential?
(Suggest an Edit or Addition)Markus Hoffmann's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor (2020) (14827)
- A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells (2020) (1343)
- The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells (2020) (710)
- SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies (2021) (696)
- The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic (2021) (561)
- Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies (2020) (443)
- Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19 (2020) (344)
- Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2 (2020) (337)
- Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination (2021) (269)
- SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination (2021) (191)
- Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity (2020) (164)
- Functional analysis of potential cleavage sites in the MERS-coronavirus spike protein (2018) (118)
- Pharmacological Inhibition of Acid Sphingomyelinase Prevents Uptake of SARS-CoV-2 by Epithelial Cells (2020) (118)
- Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity (2021) (110)
- Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants (2021) (109)
- Differential Sensitivity of Bat Cells to Infection by Enveloped RNA Viruses: Coronaviruses, Paramyxoviruses, Filoviruses, and Influenza Viruses (2013) (104)
- Priming Time: How Cellular Proteases Arm Coronavirus Spike Proteins (2018) (98)
- Mutations in the Spike Protein of Middle East Respiratory Syndrome Coronavirus Transmitted in Korea Increase Resistance to Antibody-Mediated Neutralization (2018) (97)
- SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants (2020) (93)
- LY6E impairs coronavirus fusion and confers immune control of viral disease (2020) (91)
- Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization (2021) (89)
- LY6E impairs coronavirus fusion and confers immune control of viral disease (2020) (84)
- Fusion-active glycoprotein G mediates the cytotoxicity of vesicular stomatitis virus M mutants lacking host shut-off activity. (2010) (80)
- Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods (2020) (76)
- Polymorphisms in dipeptidyl peptidase 4 reduce host cell entry of Middle East respiratory syndrome coronavirus (2020) (74)
- Different residues in the SARS-CoV spike protein determine cleavage and activation by the host cell protease TMPRSS2 (2017) (71)
- Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies (2020) (69)
- Comparative Analysis of Ebola Virus Glycoprotein Interactions With Human and Bat Cells (2011) (69)
- Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5 (2022) (65)
- SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization (2021) (59)
- Alpha-1 antitrypsin inhibits TMPRSS2 protease activity and SARS-CoV-2 infection (2021) (57)
- Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3 (2022) (56)
- Interferon-Induced Transmembrane Protein–Mediated Inhibition of Host Cell Entry of Ebolaviruses (2015) (54)
- B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination (2021) (52)
- Inhibition of acid sphingomyelinase by ambroxol prevents SARS-CoV-2 entry into epithelial cells (2021) (51)
- SARS-CoV-2 variants B.1.351 and B.1.1.248: Escape from therapeutic antibodies and antibodies induced by infection and vaccination (2021) (51)
- Erratum: Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies (Cell (2020) 181(5) (1004–1015.e15), (S0092867420304943), (10.1016/j.cell.2020.04.031)) (2020) (45)
- Molecular mechanism of inhibiting the SARS-CoV-2 cell entry facilitator TMPRSS2 with camostat and nafamostat (2020) (39)
- Omicron sublineage BQ.1.1 resistance to monoclonal antibodies (2022) (37)
- The glycoprotein of vesicular stomatitis virus promotes release of virus-like particles from tetherin-positive cells (2017) (36)
- TMPRSS11A activates the influenza A virus hemagglutinin and the MERS coronavirus spike protein and is insensitive against blockade by HAI-1 (2018) (35)
- A Polymorphism within the Internal Fusion Loop of the Ebola Virus Glycoprotein Modulates Host Cell Entry (2017) (33)
- Completion of Hepatitis C Virus Replication Cycle in Heterokaryons Excludes Dominant Restrictions in Human Non-liver and Mouse Liver Cell Lines (2011) (32)
- Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination (2021) (32)
- The Glycoproteins of All Filovirus Species Use the Same Host Factors for Entry into Bat and Human Cells but Entry Efficiency Is Species Dependent (2016) (32)
- Delta variant (B.1.617.2) sublineages do not show increased neutralization resistance (2021) (31)
- Rapid response flow cytometric assay for the detection of antibody responses to SARS-CoV-2 (2020) (28)
- SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies (2022) (27)
- Modulation of HIV-1 Gag/Gag-Pol frameshifting by tRNA abundance (2019) (27)
- A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS‐CoV‐2 infection model (2021) (27)
- Sphingosine prevents binding of SARS–CoV-2 spike to its cellular receptor ACE2 (2020) (26)
- The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency (2021) (26)
- The Hemagglutinin of Bat-Associated Influenza Viruses Is Activated by TMPRSS2 for pH-Dependent Entry into Bat but Not Human Cells (2016) (25)
- Increased lung cell entry of B.1.617.2 and evasion of antibodies induced by infection and BNT162b2 vaccination (2021) (23)
- A system for production of defective interfering particles in the absence of infectious influenza A virus (2019) (23)
- A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells (2021) (23)
- Characterization of African bat henipavirus GH-M74a glycoproteins. (2014) (22)
- Humoral and cellular immune responses against SARS-CoV-2 variants and human coronaviruses after single BNT162b2 vaccination. (2021) (22)
- Surface Glycoproteins of an African Henipavirus Induce Syncytium Formation in a Cell Line Derived from an African Fruit Bat, Hypsignathus monstrosus (2013) (21)
- Therapeutic Application of Alpha-1 Antitrypsin in COVID-19 (2021) (21)
- The Tetherin Antagonism of the Ebola Virus Glycoprotein Requires an Intact Receptor-Binding Domain and Can Be Blocked by GP1-Specific Antibodies (2016) (20)
- Mutation D614G increases SARS-CoV-2 transmission (2021) (20)
- SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination (2021) (19)
- BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19 (2021) (18)
- Tetherin Inhibits Nipah Virus but Not Ebola Virus Replication in Fruit Bat Cells (2018) (17)
- Humoral and cellular immune response against SARS-CoV-2 variants following heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. (2021) (17)
- Humoral and Cellular Immune Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants and Human Coronaviruses After Single BNT162b2 Vaccination (2021) (16)
- Spike residue 403 affects binding of coronavirus spikes to human ACE2 (2021) (16)
- The MEK1/2-inhibitor ATR-002 efficiently blocks SARS-CoV-2 propagation and alleviates pro-inflammatory cytokine/chemokine responses (2022) (16)
- A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells (2021) (15)
- Rapid SARS-CoV-2 Adaptation to Available Cellular Proteases (2020) (14)
- How SARS-CoV-2 makes the cut (2021) (14)
- Novel SARS-CoV-2 receptors: ASGR1 and KREMEN1 (2021) (14)
- Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations (2021) (14)
- Omicron: Master of immune evasion maintains robust ACE2 binding (2022) (13)
- Functional Properties and Genetic Relatedness of the Fusion and Hemagglutinin-Neuraminidase Proteins of a Mumps Virus-Like Bat Virus (2015) (13)
- Entry, Replication, Immune Evasion, and Neurotoxicity of Synthetically Engineered Bat-Borne Mumps Virus. (2018) (12)
- Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation (2022) (12)
- Improved cellular and humoral immunity upon a second BNT162b2 and mRNA-1273 boost in prime-boost vaccination no/low responders with end-stage renal disease (2021) (11)
- A GXXXA Motif in the Transmembrane Domain of the Ebola Virus Glycoprotein Is Required for Tetherin Antagonism (2018) (11)
- Calu-3 cells are largely resistant to entry driven by filovirus glycoproteins and the entry defect can be rescued by directed expression of DC-SIGN or cathepsin L (2019) (11)
- The Upper Respiratory Tract of Felids Is Highly Susceptible to SARS-CoV-2 Infection (2021) (10)
- Thiol drugs decrease SARS-CoV-2 lung injury in vivo and disrupt SARS-CoV-2 spike complex binding to ACE2 in vitro (2021) (10)
- BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults (2022) (9)
- Spike proteins of novel MERS-coronavirus isolates from North- and West-African dromedary camels mediate robust viral entry into human target cells (2019) (9)
- Augmented neutralization of SARS‐CoV‐2 Omicron variant by boost vaccination and monoclonal antibodies (2022) (9)
- Cell Entry of Influenza A Viruses: Sweet Talk between HA and CaV1.2. (2018) (8)
- Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2 (2020) (8)
- LRRC15 mediates an accessory interaction with the SARS-CoV-2 spike protein (2021) (8)
- Virion Background and Efficiency of Virion Incorporation Determine Susceptibility of Simian Immunodeficiency Virus Env-Driven Viral Entry to Inhibition by IFITM Proteins (2016) (8)
- Attachment Protein G of an African Bat Henipavirus Is Differentially Restricted in Chiropteran and Nonchiropteran Cells (2014) (8)
- Novel surrogate virus neutralization test reveals low serum neutralizing anti-SARS-CoV-2-S antibodies levels in mildly affected COVID-19 convalescents (2020) (8)
- Dynamic Ca2+ sensitivity stimulates the evolved SARS-CoV-2 spike strain-mediated membrane fusion for enhanced entry (2022) (7)
- Exploring antiviral and anti-inflammatory effects of thiol drugs in COVID-19 (2022) (7)
- Lung cell entry, cell–cell fusion capacity, and neutralisation sensitivity of omicron sublineage BA.2.75 (2022) (7)
- Synergistic inhibition of SARS-CoV-2 cell entry by otamixaban and covalent protease inhibitors: pre-clinical assessment of pharmacological and molecular properties (2021) (7)
- Release of Immunomodulatory Ebola Virus Glycoprotein-Containing Microvesicles Is Suppressed by Tetherin in a Species-Specific Manner. (2019) (7)
- Evidence for an ACE2-Independent Entry Pathway That Can Protect from Neutralization by an Antibody Used for COVID-19 Therapy (2022) (6)
- Fusogenicity of the Ghana Virus (Henipavirus: Ghanaian bat henipavirus) Fusion Protein is Controlled by the Cytoplasmic Domain of the Attachment Glycoprotein (2019) (5)
- Neutralizing antibody responses 300 days after SARS‐CoV‐2 infection and induction of high antibody titers after vaccination (2022) (5)
- Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2 (2022) (5)
- No evidence for increased cell entry or antibody evasion by Delta sublineage AY.4.2 (2022) (5)
- Recombinant mumps viruses expressing the batMuV fusion glycoprotein are highly fusion active and neurovirulent. (2016) (5)
- Native and activated antithrombin inhibits TMPRSS2 activity and SARS‐CoV‐2 infection (2022) (4)
- Disease Manifestation and Viral Sequences in a Bonobo More Than 30 Years after Papillomavirus Infection (2019) (4)
- Analysis of Resistance of Ebola Virus Glycoprotein-Driven Entry Against MDL28170, An Inhibitor of Cysteine Cathepsins (2019) (4)
- Dalbavancin: novel candidate for COVID-19 treatment (2021) (4)
- Functional analysis of polymorphisms at the S1/S2 site of SARS-CoV-2 spike protein (2022) (4)
- Neutralisation sensitivity of the SARS-CoV-2 XBB.1 lineage (2023) (4)
- The effect of cilgavimab and neutralisation by vaccine-induced antibodies in emerging SARS-CoV-2 BA.4 and BA.5 sublineages (2022) (3)
- Protective mucosal immunity against SARS-CoV-2 after heterologous systemic RNA-mucosal adenoviral vector immunization (2021) (3)
- Peptidomimetic inhibitors of TMPRSS2 block SARS-CoV-2 infection in cell culture (2022) (3)
- Author response for "A pair of non‐competing neutralizing human monoclonal antibodies protecting from disease in a SARS‐CoV‐2 infection model" (2021) (3)
- Ex vivo assay to evaluate the efficacy of drugs targeting sphingolipids in preventing SARS-CoV-2 infection of nasal epithelial cells (2021) (3)
- TMPRSS2 Is Essential for SARS-CoV-2 Beta and Omicron Infection (2022) (3)
- A surrogate cell‐based SARS‐CoV‐2 spike blocking assay (2021) (3)
- Profound neutralization evasion and augmented host cell entry are hallmarks of the fast-spreading SARS-CoV-2 lineage XBB.1.5 (2023) (3)
- MCMV-based vaccine vectors expressing full-length viral proteins provide long-term humoral immune protection upon a single-shot vaccination (2021) (2)
- Mutagenic Analysis of the HIV Restriction Factor Shiftless (2022) (2)
- The SARS-CoV-2 Delta-Omicron Recombinant Lineage (XD) Exhibits Immune-Escape Properties Similar to the Omicron (BA.1) Variant (2022) (2)
- SARS-CoV-2 variants C.1.2 and B.1.621 (Mu) partially evade neutralization by antibodies elicited upon infection or vaccination (2022) (2)
- Inhibition of Acid Sphingomyelinase Blocks Infection with SARS-CoV-2 (2020) (2)
- Interferon induction and not replication interference mainly determines anti-influenza virus activity of defective interfering particles (2021) (1)
- Understanding Omicron: Transmissibility, immune evasion and antiviral intervention (2022) (1)
- 24 People, one test: Boosting test efficiency using pooled serum antibody testing for SARS-CoV-2 (2020) (1)
- Nafamostat-Mediated Inhibition of SARS-CoV-2 Ribosomal Frameshifting Is Insufficient to Impair Viral Replication in Vero Cells. Comment on Munshi et al. Identifying Inhibitors of −1 Programmed Ribosomal Frameshifting in a Broad Spectrum of Coronaviruses. Viruses 2022, 14, 177 (2022) (1)
- SARS-CoV-2 neutralizing camelid heavy-chain-only antibodies as powerful tools for diagnostic and therapeutic applications (2022) (1)
- SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades 1 antibodies induced by infection and vaccination (2021) (1)
- The Amino Acid at Position 8 of the Proteolytic Cleavage Site of the Mumps Virus Fusion Protein Affects Viral Proteolysis and Fusogenicity (2020) (0)
- Host Cell Entry and Neutralization Sensitivity of SARS-CoV-2 Lineages B.1.620 and R.1 (2022) (0)
- In-depth analysis of T cell immunity and antibody responses in heterologous prime-boost-boost vaccine regimens against SARS-CoV-2 and Omicron variant (2022) (0)
- Publisher Correction: Dalbavancin: novel candidate for COVID-19 treatment (2022) (0)
- Development and Evaluation of Peptidomimetic Compounds against SARS‐CoV‐2 Spike Protein: An in silico and in vitro Study (2022) (0)
- 40 COMPLETION OF HEPATITIS C VIRUS REPLICATION CYCLE IN HETEROKARYONS EXCLUDES DOMINANT RESTRICTION FACTORS IN HUMAN NON-LIVER AND MOUSE LIVER CELL LINES (2011) (0)
- Bat, Hypsignathus monstrosus a Cell Line Derived from an African Fruit in Henipavirus Induce Syncytium Formation Surface Glycoproteins of an African (2014) (0)
- MCMV-based vaccine vectors expressing full-length viral proteins provide long-term humoral immune protection upon a single-shot vaccination (2022) (0)
- Inside Back Cover Image, Volume 95, Number 1, January 2023 (2023) (0)
- Novel SARS-CoV-2 receptors: ASGR1 and KREMEN1 (2021) (0)
- Long-term immune protection against SARS-CoV-2 escape variants upon a single vaccination with murine cytomegalovirus expressing the spike protein (2022) (0)
- SARS-CoV-2 vaccination of laboratory rhesus monkeys (Macaca mulatta): Monitoring and efficacy (2022) (0)
- SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization - A study of M. Hoffmann et al. (2021) (0)
- The MEK1/2-inhibitor ATR-002 efficiently blocks SARS-CoV-2 propagation and alleviates pro-inflammatory cytokine/chemokine responses (2022) (0)
- Monitoring and immunogenicity of SARS-CoV-2 vaccination of laboratory rhesus monkeys (Macaca mulatta) (2023) (0)
- Functional analysis of potential cleavage sites in the MERS-coronavirus spike protein (2018) (0)
- Efficient antibody evasion but reduced ACE2 binding by the emerging SARS-CoV-2 variant B.1.640.2 (2022) (0)
- Omicron spike protein: a clue for viral entry and immune evasion (2022) (0)
- No evidence for increased cell entry or antibody evasion by Delta sublineage AY.4.2 (2022) (0)
- Role of rhesus macaque IFITM3(2) in simian immunodeficiency virus infection of macaques (2019) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Markus Hoffmann?
Markus Hoffmann is affiliated with the following schools:
